An experimental shingles vaccine from GlaxoSmithKline is effective across all age groups, researchers said on Tuesday, boosting the prospects of a key product in the British drugmaker's development pipeline. In contrast to Merck's established Zostavax, currently the only product on the market, GSK's vaccine HZ/su showed no diminution in efficacy with age, according to detailed results from a large Phase III trial.